NasdaqGS:PCRXPharmaceuticals
A Look At Pacira BioSciences (PCRX) Valuation After New EXPAREL Health Economic Data
Pacira BioSciences (PCRX) shares recently reacted to fresh health economic data on its flagship non opioid pain drug, EXPAREL, following presentations at the Academy of Managed Care Pharmacy Annual 2026 Meeting in Nashville.
See our latest analysis for Pacira BioSciences.
The new EXPAREL health economic data arrives alongside a 90 day share price return of 28.08% and a 30 day share price return of 11.80%. However, the 1 year total shareholder return of 4.56% and 5 year total shareholder...